Testosterone Lab Testing and Initiation in the United Kingdom and the United States, 2000 to 2011
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
CONTEXT: New formulations, increased marketing, and wider recognition of declining testosterone levels in older age may have contributed to wider testosterone testing and supplementation in many countries. OBJECTIVE: Our objective was to describe testosterone testing and testosterone treatment in men in the United Kingdom and United States. DESIGN: This was a retrospective incident user cohort. SETTING: We evaluated commercial and Medicare insurance claims from the United States and general practitioner healthcare records from the United Kingdom for the years 2000 through 2011. PARTICIPANTS: We identified 410,019 US men and 6858 UK men who initiated a testosterone formulation as well as 1,114,329 US men and 66,140 UK men with a new testosterone laboratory measurement. MAIN OUTCOME MEASURES: Outcome measures included initiation of any injected testosterone, implanted testosterone pellets, or prescribed transdermal or oral testosterone formulation. RESULTS: Testosterone testing and supplementation have increased pronouncedly in the United States. Increased testing in the United Kingdom has identified more men with low levels, yet US testing has increased among men with normal levels. Men in the United States tend to initiate at normal levels more often than in the United Kingdom, and many men initiate testosterone without recent testing. Gels have become the most common initial treatment in both countries. CONCLUSIONS: Testosterone testing and use has increased over the past decade, particularly in the United States, with dramatic shifts from injections to gels. Substantial use is seen in men without recent testing and in US men with normal levels. Given widening use despite safety and efficacy questions, prescribers must consider the medical necessity of testosterone before initiation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Feldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861
Adverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Vigen, R. (2013) · JAMA · doi:10.1001/jama.2013.280386 · Cited by 1,003 · cited 2×
“The observed increases in use are potentially troubling in light of recent reports of increased risks associated with testosterone use: death, myocardial infarction, and stroke in an observational study of older men with cardiovascular disease and hypogonadism (30) and cardiovascular events from a meta-analysis of tes…”
BackgroundWu, F. C. W., Tajar, A., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F., Forti, G., Giwercman, A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1972 · Cited by 939 · cited 1×
“However, testosterone levels gradually decrease with increasing age (2–6) and in the presence of chronic diseases (4, 5, 7, 8), obesity (4, 5, 7), and smoking (5).”
BackgroundInvestigation, treatment and monitoring of late-onset hypogonadism in males
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0601 · Cited by 867
Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men
Finkelstein, J. S., Lee, H., Burnett-Bowie, S.-A. M., Pallais, J. C., Yu, E. W., Borges, L. F., Jones, B. F., Barry, C. V., Wulczyn, K. E., Thomas, B. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1206168 · Cited by 782
Prevalence of hypogonadism in males aged at least 45 years: the HIM study
MULLIGAN, T., FRICK, M. F., ZURAW, Q. C., STEMHAGEN, A., & MCWHIRTER, C. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.00992.x · Cited by 767 · cited 1×
“However, testosterone levels gradually decrease with increasing age (2–6) and in the presence of chronic diseases (4, 5, 7, 8), obesity (4, 5, 7), and smoking (5).”
BackgroundCalof, O. M., Singh, A. B., Lee, M. L., Kenny, A. M., Urban, R. J., Tenover, J. L., & Bhasin, S. (2005) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/60.11.1451 · Cited by 728
Prevalence of Symptomatic Androgen Deficiency in Men
Araujo, A. B., Esche, G. R., Kupelian, V., O’Donnell, A. B., Travison, T. G., Williams, R. E., Clark, R. V., & McKinlay, J. B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1245 · Cited by 720 · cited 1×
“older men with lower testosterone levels (6) without fully”
BackgroundTrends in androgen prescribing in the United States, 2001 to 2011
Baillargeon, J., Urban, R. J., Ottenbacher, K. J., Pierson, K. S., & Goodwin, J. S. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6895 · Cited by 336
Handelsman, D. J. (2013) · Medical Journal of Australia · doi:10.5694/mja13.10111 · Cited by 253 · cited 1×
“However, the recognition of individuals with age-related reduced testosterone is increasing, and recent reports suggest increased testosterone use in the United Kingdom (15), the United States (16), and other countries around the world (17, 18).”
BackgroundWide Variability in Laboratory Reference Values for Serum Testosterone
Lazarou, S., Reyes-Vallejo, L., & Morgentaler, A. (2006) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2006.00334.x · Cited by 83
Yun, Y.-M., Botelho, J. C., Chandler, D. W., Katayev, A., Roberts, W. L., Stanczyk, F. Z., Vesper, H. W., Nakamoto, J. M., Garibaldi, L., Clarke, N. J., et al. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.186569 · Cited by 36 · cited 1×
“Additionally, there is wide variation in assay results between laboratories (21, 22) complicating identification of clinically meaningful reduced testosterone levels when applying common reference ranges to results from different testing facilities.”
Testosterone therapy in older men with late-onset hypogonadism: a counter-rationale
Basaria, S. (2013) · Endocrine Practice · doi:10.4158/ep13318.ra · Cited by 18
Cited by
Epidemiology and prevention of venous thromboembolism
Lutsey, P. L., & Zakai, N. A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00787-6 · Cited by 507
Yeap, B. B., Grossmann, M., McLachlan, R. I., Handelsman, D. J., Wittert, G. A., Conway, A. J., Stuckey, B. G., Lording, D. W., Allan, C. A., Zajac, J. D., et al. (2016) · Medical Journal of Australia · doi:10.5694/mja16.00393 · Cited by 135
Cooper, L. A., Page, S. T., Amory, J. K., Anawalt, B. D., & Matsumoto, A. M. (2015) · Clinical Endocrinology · doi:10.1111/cen.12768 · Cited by 117
Testosterone replacement therapy: for whom, when and how?
Tsametis, C. P., & Isidori, A. M. (2018) · Metabolism · doi:10.1016/j.metabol.2018.03.007 · Cited by 96
Tatem, A. J., Beilan, J., Kovac, J. R., & Lipshultz, L. I. (2020) · The World Journal of Men's Health · doi:10.5534/wjmh.190002 · Cited by 66
Metadata
- Authors
- Layton, J. B., Li, D., Meier, C. R., Sharpless, J. L., Stürmer, T., Jick, S. S., & Brookhart, M. A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2014-03-01
- Volume
- 99
- Issue
- 3
- Pages
- 835-842
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1997277684
- Cited by
- 195
- References
- 16
- FWCI
- 21.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.